Marksans Pharma Financial Results
- Market cap
- ₹14,737 crore
- P/E
- 28.5
- P/B
- 4.87
- ROE
- 15.2%
- Dividend yield
- 0.28%
For the year ended Mar 2019, Marksans Pharma reported revenue of ₹1,000 crore and net profit of ₹80 crore, against ₹1,134 crore and ₹121 crore a year earlier.
Marksans Pharma annual profit and loss
Financial years, newest first. TTM = trailing twelve months.
| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,000 | 1,134 | 1,376 | 1,491 | 1,850 | 2,174 | 2,614 | 2,942 | 3,172 |
| Expenses | 868 | 942 | 1,037 | 1,232 | 1,485 | 1,712 | 2,075 | 2,328 | 2,458 |
| Operating profit | 132 | 192 | 340 | 259 | 365 | 462 | 539 | 614 | 714 |
| Operating margin % | 13% | 17% | 25% | 17% | 20% | 21% | 21% | 21% | 23% |
| Other income | 5 | 0 | 7 | 42 | 30 | 47 | 60 | 69 | 102 |
| Interest | 10 | 9 | 8 | 8 | 6 | 11 | 12 | 24 | 25 |
| Depreciation | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 99 | 100 |
| Profit before tax | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 561 | 691 |
| Tax % | 23% | 23% | 21% | 25% | 21% | 26% | 24% | 25% | 25% |
| Net profit | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 420 | 521 |
| EPS (₹) | 1.70 | 2.70 | 5.34 | 4.18 | 5.96 | 6.92 | 8.40 | 9.22 | 11.40 |
| Dividend payout % | — | — | — | — | — | — | — | — | — |
Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Marksans Pharma financial results — frequently asked questions
What is Marksans Pharma's annual revenue and net profit?
For the financial year ended Mar 2019, Marksans Pharma's revenue was ₹1,000 crore and net profit ₹80 crore; net profit fell 33.88% from ₹121 crore in Mar 2020.
How fast has Marksans Pharma grown over three years?
From Mar 2022 to Mar 2019, Marksans Pharma's revenue grew at a compound annual rate of -12.5% and net profit at -24.7%. Past growth does not indicate future results.
What is the EPS of Marksans Pharma?
Annual EPS for Mar 2019 was ₹1.70.
Are these figures consolidated or standalone?
They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.
Same Data For Peers
Trade Marksans Pharma With ATS
Track MARKSANS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.